Evaluation	0	10	O
of	11	13	O
electrical	14	24	O
stimulation	25	36	O
for	37	40	O
ischemic	41	49	O
wound	50	55	O
therapy	56	63	O
:	63	64	O
a	65	66	O
feasibility	67	78	O
study	79	84	O
using	85	90	O
the	91	94	O
lapine	95	101	O
wound	102	107	O
model	108	113	O
.	113	114	O

Chronic	116	123	O
wounds	124	130	O
are	131	134	O
a	135	136	O
major	137	142	O
secondary	143	152	O
complication	153	165	O
for	166	169	O
many	170	174	O
people	175	181	B-Organism
with	182	186	O
impaired	187	195	O
mobility	196	204	O
.	204	205	O

Electrical	206	216	O
stimulation	217	228	O
(	229	230	O
ES	230	232	O
)	232	233	O
has	234	237	O
been	238	242	O
recommended	243	254	O
as	255	257	O
a	258	259	O
adjunctive	260	270	O
therapy	271	278	O
,	278	279	O
however	280	287	O
optimal	288	295	O
treatment	296	305	O
paradigms	306	315	O
have	316	320	O
not	321	324	O
been	325	329	O
established	330	341	O
.	341	342	O

Our	343	346	O
group	347	352	O
seeks	353	358	O
to	359	361	O
determine	362	371	O
the	372	375	O
basic	376	381	O
mechanisms	382	392	O
underlying	393	403	O
ES	404	406	O
wound	407	412	O
therapy	413	420	O
,	420	421	O
an	422	424	O
area	425	429	O
where	430	435	O
understanding	436	449	O
is	450	452	O
currently	453	462	O
limited	463	470	O
.	470	471	O

A	472	473	O
feasibility	474	485	O
study	486	491	O
was	492	495	O
carried	496	503	O
out	504	507	O
to	508	510	O
develop	511	518	O
the	519	522	O
Ahn	523	526	O
/	526	527	O
Mustoe	527	533	O
lapine	534	540	O
wound	541	546	O
model	547	552	O
for	553	556	O
systematic	557	567	O
investigation	568	581	O
of	582	584	O
the	585	588	O
effects	589	596	O
of	597	599	O
electrical	600	610	O
stimulation	611	622	O
on	623	625	O
ischemic	626	634	O
wound	635	640	O
therapy	641	648	O
.	648	649	O

A	650	651	O
standardized	652	664	O
surgical	665	673	O
procedure	674	683	O
incorporated	684	696	O
a	697	698	O
hybrid	699	705	O
stimulation	706	717	O
system	718	724	O
comprising	725	735	O
an	736	738	O
implantable	739	750	O
mini	751	755	O
-	755	756	O
stimulator	756	766	O
and	767	770	O
surface	771	778	O
electrodes	779	789	O
,	789	790	O
with	791	795	O
creation	796	804	O
of	805	807	O
repeatable	808	818	O
ischemic	819	827	O
wounds	828	834	O
.	834	835	O

Twenty	836	842	O
mature	843	849	O
male	850	854	O
New	855	858	O
Zealand	859	866	O
white	867	872	O
rabbits	873	880	B-Organism
(	881	882	O
3	882	883	O
kg	884	886	O
weight	887	893	O
)	893	894	O
were	895	899	O
employed	900	908	O
to	909	911	O
evaluate	912	920	O
the	921	924	O
effects	925	932	O
of	933	935	O
two	936	939	O
empirically	940	951	O
selected	952	960	O
stimulation	961	972	O
paradigms	973	982	O
applied	983	990	O
continuously	991	1003	O
for	1004	1007	O
7	1008	1009	O
-	1009	1010	O
21	1010	1012	O
days	1013	1017	O
,	1017	1018	O
using	1019	1024	O
each	1025	1029	O
animal	1030	1036	O
as	1037	1039	O
its	1040	1043	O
own	1044	1047	O
control	1048	1055	O
.	1055	1056	O

Outcomes	1057	1065	O
measures	1066	1074	O
included	1075	1083	O
transcutaneous	1084	1098	O
blood	1099	1104	B-Organism_substance
gas	1105	1108	O
levels	1109	1115	O
,	1115	1116	O
histology	1117	1126	O
,	1126	1127	O
total	1128	1133	O
RNA	1134	1137	O
content	1138	1145	O
and	1146	1149	O
analysis	1150	1158	O
of	1159	1161	O
alpha2	1162	1168	B-Gene_or_gene_product
(	1169	1170	I-Gene_or_gene_product
I	1170	1171	I-Gene_or_gene_product
)	1171	1172	I-Gene_or_gene_product
collagen	1173	1181	I-Gene_or_gene_product
(	1182	1183	O
COL	1183	1186	B-Gene_or_gene_product
-	1186	1187	I-Gene_or_gene_product
I	1187	1188	I-Gene_or_gene_product
)	1188	1189	O
,	1189	1190	O
type	1191	1195	B-Gene_or_gene_product
IV	1196	1198	I-Gene_or_gene_product
collagen	1199	1207	I-Gene_or_gene_product
(	1208	1209	O
COL	1209	1212	B-Gene_or_gene_product
-	1212	1213	I-Gene_or_gene_product
IV	1213	1215	I-Gene_or_gene_product
)	1215	1216	O
,	1216	1217	O
alpha1	1218	1224	B-Gene_or_gene_product
(	1225	1226	I-Gene_or_gene_product
V	1226	1227	I-Gene_or_gene_product
)	1227	1228	I-Gene_or_gene_product
collagen	1229	1237	I-Gene_or_gene_product
(	1238	1239	O
COL	1239	1242	B-Gene_or_gene_product
-	1242	1243	I-Gene_or_gene_product
V	1243	1244	I-Gene_or_gene_product
)	1244	1245	O
,	1245	1246	O
and	1247	1250	O
vascular	1251	1259	B-Gene_or_gene_product
endothelial	1260	1271	I-Gene_or_gene_product
growth	1272	1278	I-Gene_or_gene_product
factor	1279	1285	I-Gene_or_gene_product
(	1286	1287	O
VEGF	1287	1291	B-Gene_or_gene_product
)	1291	1292	O
expression	1293	1303	O
using	1304	1309	O
real	1310	1314	O
-	1314	1315	O
time	1315	1319	O
quantitative	1320	1332	O
PCR	1333	1336	O
.	1336	1337	O

All	1338	1341	O
markers	1342	1349	O
for	1350	1353	O
stimulated	1354	1364	O
wounds	1365	1371	O
showed	1372	1378	O
increased	1379	1388	O
activity	1389	1397	O
relative	1398	1406	O
to	1407	1409	O
non	1410	1413	O
-	1413	1414	O
stimulated	1414	1424	O
control	1425	1432	O
wounds	1433	1439	O
between	1440	1447	O
7	1448	1449	O
and	1450	1453	O
14	1454	1456	O
days	1457	1461	O
following	1462	1471	O
injury	1472	1478	O
,	1478	1479	O
with	1480	1484	O
peak	1485	1489	O
activity	1490	1498	O
at	1499	1501	O
14	1502	1504	O
days	1505	1509	O
.	1509	1510	O

By	1511	1513	O
21	1514	1516	O
days	1517	1521	O
post	1522	1526	O
-	1526	1527	O
injury	1527	1533	O
,	1533	1534	O
all	1535	1538	O
activity	1539	1547	O
had	1548	1551	O
returned	1552	1560	O
to	1561	1563	O
near	1564	1568	O
baseline	1569	1577	O
level	1578	1583	O
.	1583	1584	O

VEGF	1585	1589	B-Gene_or_gene_product
and	1590	1593	O
COL	1594	1597	B-Gene_or_gene_product
-	1597	1598	I-Gene_or_gene_product
IV	1598	1600	I-Gene_or_gene_product
levels	1601	1607	O
were	1608	1612	O
found	1613	1618	O
to	1619	1621	O
be	1622	1624	O
significantly	1625	1638	O
higher	1639	1645	O
for	1646	1649	O
pattern	1650	1657	O
A	1658	1659	O
(	1660	1661	O
110	1661	1664	O
mus	1665	1668	O
pulse	1669	1674	O
width	1675	1680	O
)	1680	1681	O
compared	1682	1690	O
to	1691	1693	O
pattern	1694	1701	O
B	1702	1703	O
(	1704	1705	O
5	1705	1706	O
mus	1707	1710	O
pulse	1711	1716	O
width	1717	1722	O
)	1722	1723	O
at	1724	1726	O
14	1727	1729	O
days	1730	1734	O
,	1734	1735	O
implying	1736	1744	O
that	1745	1749	O
pattern	1750	1757	O
A	1758	1759	O
may	1760	1763	O
be	1764	1766	O
more	1767	1771	O
effective	1772	1781	O
at	1782	1784	O
promoting	1785	1794	O
angiogenesis	1795	1807	O
.	1807	1808	O

All	1809	1812	O
wounds	1813	1819	O
were	1820	1824	O
fully	1825	1830	O
re	1831	1833	O
-	1833	1834	O
epithelialized	1834	1848	O
by	1849	1851	O
10	1852	1854	O
days	1855	1859	O
post	1860	1864	O
-	1864	1865	O
injury	1865	1871	O
.	1871	1872	O

Both	1873	1877	O
COL	1878	1881	B-Gene_or_gene_product
-	1881	1882	I-Gene_or_gene_product
I	1882	1883	I-Gene_or_gene_product
and	1884	1887	O
COL	1888	1891	B-Gene_or_gene_product
-	1891	1892	I-Gene_or_gene_product
V	1892	1893	I-Gene_or_gene_product
showed	1894	1900	O
statistically	1901	1914	O
significant	1915	1926	O
(	1927	1928	O
P	1928	1929	O
less	1931	1935	O
than	1936	1940	O
0	1942	1943	O
.	1943	1944	O
05	1944	1946	O
)	1946	1947	O
increased	1948	1957	O
activity	1958	1966	O
between	1967	1974	O
day	1975	1978	O
7	1979	1980	O
and	1981	1984	O
day	1985	1988	O
14	1989	1991	O
for	1992	1995	O
pattern	1996	2003	O
A	2004	2005	O
,	2005	2006	O
potentially	2007	2018	O
indicating	2019	2029	O
a	2030	2031	O
continued	2032	2041	O
effect	2042	2048	O
on	2049	2051	O
matrix	2052	2058	B-Cellular_component
remodeling	2059	2069	O
.	2069	2070	O

The	2071	2074	O
early	2075	2080	O
closure	2081	2088	O
of	2089	2091	O
all	2092	2095	O
wounds	2096	2102	O
implies	2103	2110	O
that	2111	2115	O
the	2116	2119	O
rabbit	2120	2126	B-Organism
ear	2127	2130	B-Organ
model	2131	2136	O
may	2137	2140	O
not	2141	2144	O
be	2145	2147	O
valid	2148	2153	O
for	2154	2157	O
chronic	2158	2165	O
wound	2166	2171	O
studies	2172	2179	O
.	2179	2180	O

